AccScience Publishing / ITPS / Volume 6 / Issue 2 / DOI: 10.36922/itps.0618
Cite this article
Journal Browser
Volume | Year
News and Announcements
View All

Evaluation of genotoxicity of (4-fluorophenyl) thiazolidin-4-one in CHO-K1 cells

Jhansi Mamilla1† Kalpana Javvaji1,3† Kavya Lekha Sunkara1 Umesh B. Kosurkar2 Ravindra M. Kumbhare2,3* Sunil Misra1,3*
Show Less
1 Genetic Toxicology Lab, Applied Biology, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India
2 Department of Fluoro-Agrochemicals, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India
3 Academy of Scientific and Innovative Research, Ghaziabad, India
INNOSC Theranostics and Pharmacological Sciences 2023, 6(2), 0618
Submitted: 18 April 2023 | Accepted: 18 July 2023 | Published: 7 August 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( )

4-thiazolidinones are five-membered heterocyclic ring compounds with diverse pharmacological impacts. In a previous study, we reported a series of newly synthesized derivatives of 4-thiazolidinones with different functional groups, which exhibited anticancer activity against ovarian (SKOV3) and cervical (HeLa) cancer cell lines. Among these derivatives, (4-fluorophenyl) thiazolidin-4-one (4-TH) demonstrated potent cytotoxic activity against SKOV3, with an IC50 value of 12.3 μM. However, it was also found to be extremely toxic to normal cells (CHO-K1) with an IC50 of 7.5 μM. Before considering its use in cancer research, it is crucial to gain a comprehensive understanding of its potential genotoxic effects on normal cells. In this study, we aimed to assess the in vitro cytogenetic toxicity of 4-TH using normal Chinese hamster ovary cells (CHO-K1). Referring to the IC50 of 4-TH, we selected three sub-lethal concentrations (2, 5, and 7.5 μM) and treated CHO-K1 cells for 24 h (one cell cycle duration) to estimate its dose-dependent induction of chromosome aberrations, and examine the effect of 4-TH on cell division, micronucleus induction potential and cell cycle arrest properties following standard protocols. The results showed that 4-TH was highly toxic to normal cells, as all three sublethal concentrations caused a statistically significant increase in the number of chromosomal aberrations (P < 0.001), formation of micronuclei (P < 0.01), and changes in the rate of cell division (mitotic index) (P < 0.05) compared to control. In addition, there was a significant increase in the number of cells in the G1 phase, indicating that all concentrations of 4-TH tested induced apoptosis. The evaluation of the cytotoxic, clastogenic, and aneugenic properties of 4-TH, a potent cytotoxic agent, will undoubtedly provide critical information for determining its safety and potential as an anticancer drug.

Chromosome aberration
Mitotic index
Cell cycle
  1. Brown FC, 1961, 4-Thiazolidinones. Chem Rev, 61: 463–521.


  1. Jain AK, Vaidya A, Ravichandran V, et al., 2012, Recent developments and biological activities of thiazolidinone derivatives: A review. Bioog Med Chem, 20: 3378–3395.


  1. Tripathi AC, Gupta SJ, Fatima G, et al., 2014, 4-Thiazolidinones: The advances continue. Eur J Med Chem, 72, 52–77.


  1. Thomas B, LS A, Harindran J, 2014, Novel Mannich bases of 4-thiazolidinone derivatives as antitubercular agents. Int J Res Pharm Chem, 4: 351–359.


  1. Patel NB, Shaikh FM, 2010, Synthesis and antimicrobial activity of new 4-thiazolidinone derivatives containing 2-amino-6- methoxybenzothiazole. Saudi Pharm J, 18: 129–136.


  1. Vicini P, Geronikaki A, Anastasia K, et al., 2006, Synthesis and antimicrobial activity of novel 2-thiazolylimino-5-arylidene- 4-thiazolidinones. Bioorg Med Chem, 14: 3859–3864.


  1. Ulusoy N, Ergenç N, Ekinci AC, et al., 1996, Synthesis and anticonvulsant activity of some new arylidenehydrazides and 4-thiazolidinones. Mon Chem/Chem Mon, 127: 1197–1202.


  1. Archana, Srivastava VK, Kumar A, 2002, Synthesis of newer thiadiazolyl and thiazolidinonyl quinazolin-4 3H-ones as potential anticonvulsant agents. Eur J Med Chem, 37: 873–882.


  1. Shiradkar MR, Ghodake M, Bothara KG, et al., 2007, Synthesis and anticonvulsant activity of clubbed thiazolidinone-barbituric acid and thiazolidinone-triazole derivatives. Arkivoc, 14: 58-74.


  1. Ottana R, Maccari R, Barreca ML, et al., 2005, 5-Arylidene- 2-imino-4-thiazolidinones: Design and synthesis of novel anti-inflammatory agents. Bioorg Med Chem, 13: 4243–4252.


  1. Boyd MR, Paull KD, 1995, Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res, 34: 91–109.


  1. Carter PH, Scherle PA, Muckelbauer JA, et al., 2001, Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha. Proc Natl Acad Sci, 98: 11879–11884.


  1. Cutshall NS, O’Day C, Prezhdo M, 2005, Rhodanine derivatives as inhibitors of JSP-1. Bioorg Med Chem Lett, 15: 3374–3379.


  1. Look GC, Schullek JR, Holmes CP, et al., 1996, The identification of cyclooxygenase-1 inhibitors from 4-thiazolidinone combinatorial libraries. Bioorg Med Chem Let, 6: 707–712.


  1. Barreca ML, Chimirri A, De Luca L, et al., 2001, Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg Med Chem Lett, 11: 1793–1796.


  1. Rao A, Carbone A, Chimirri A, et al., 2002, Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives. Il Farmaco, 57: 747–751.


  1. Rao A, Balzarini J, Carbone A, et al., 2004, Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Il Farmaco, 59: 33–39.


  1. Balzarini J, Orzeszko B, Maurin JK, et al., 2007, Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4- ones. Eur J Med Chem, 42: 993–1003.


  1. Rao A, Chimirri A, Ferro S, et al., 2004, Microwave-induced synthesis of benzimidazole and thiazolidinone derivatives as HIV-1 RT inhibitors. Arkivoc, 5: 147–155.


  1. Ravichandran V, Kumar BP, Sankar S, 2009, Predicting anti- HIV activity of 1,3,4-thiazolidinone derivaties: 3D-QSAR approach. Eur J Med Chem, 44: 1180–1187.


  1. Mosula L, Zimenkovsky B, Havrylyuk D, et al., 2009, Synthesis and antitumor activity of novel 2-thioxo-4- thiazolidinones with benzothiazole moieties. Farmacia, 57: 321–330.


  1. Dua R, Shrivastava S, Sonwane SK, et al., 2011, Pharmacological significance of synthetic heterocycles scaffold: A review. Adv Biol Res, 5: 20–144.


  1. Zahradnik M, 1983, The Production and Application of Fluorescent Brightening Agents. Translated by Wilkinson Procharzka ZF. Chichester: Wiley-Interscience, p147.


  1. Naganna MG, Rohini YR, 2014, Synthesis antimicrobial and antioxidant evaluation of 3-(2-(4-fluorobenzylthio) pyrimidin-4-yl-amino)-2-(3-substituted phenyl) thiazolidin-4-ones. World J Pharm Pharm Sci, 3: 1094–1109.


  1. Liu HL, Li Z, Anthonsen T, 2000, Synthesis and fungicidal activity of 2-imino-3-(4-arylthiazol-2-yl)-thiazolidin-4-ones and their 5-arylidene derivatives. Molecules, 5: 1055–1061.


  1. Radin NS, 2008, Drug design: Hiding in full view. Drug Dev Res, 69: 15–25.


  1. Thomas AB, Nanda RK, Kothapalli LP, et al., 2013, Synthesis, biological activity, molecular modelling studies and 3D-QSAR Investigations of N-[2-(aryl/substituted aryl)-4- oxo-1, 3-thiazolidin-3-yl] pyridine-4-carboxamides. Open Conf Proc J, 4: 99–112.


  1. Taranalli AD, Bhat AR, Srinivas S, et al., 2008, Antiinflammatory,analgesic and antipyretic activity of certain thiazolidinones. Indian J Pharm Sci, 70: 159.


  1. Kosurkar UB, Mamilla J, Dadmal TL, et al., 2023, Synthesis of novel Thiazolidine-4-One derivatives, their cytotoxicity, antifungal properties, molecular docking and molecular dynamics. Rus J Bioorg Chem, 49, 314–323.


  1. Gandhi B, Juliya J, Dileep V, et al., 2021, Antioxidant and biological activities of novel structured monoacylglycerol derivatives with phenolic acids. Eur J Lipid Sci Technol, 123: 2100055.


  1. Deshpande SS, Veeragoni D, Rachamalla HK, et al., 2022, Anticancer properties of ZnO-Curcumin nanocomposite against melanoma cancer and its genotoxicity profiling. J Drug Deliv Sci Tech, 75: 103703.


  1. Choudante PC, Nethi SK, Díaz-García D, et al., 2022, Tin-loaded mesoporous silica nanoparticles: Antineoplastic properties and genotoxicity assessment. Biomater Adv, 137: 212819.


  1. Javvaji K, Mamilla J, Kongari L, et al., 2023, In vitro cytogenetic toxicity and cell cycle arrest profiling of fluorinated trifluoromethyl 4-Thiazolidinone on CHO-K1 cells. Arch Clin Toxicol, 5: 1–8.


  1. Bhat M, Poojary B, Kalal BS, et al., 2018, Synthesis and evaluation of thiazolidinone-pyrazole conjugates as anticancer and antimicrobial agents. Future Med Chem, 10: 1017–1036.


  1. Djukic M, Fesatidou M, Xenikakis I, et al., 2018, In vitro antioxidant activity of thiazolidinone derivatives of 1,3-thiazole and 1,3,4-thiadiazole. Chem Biol Interact, 286: 119–131.


  1. Dillehay LE, Denstman SC, Williams JR, 1987, Cell cycle dependence of sister chromatid exchange induction by DNA topoisomerase II inhibitors in Chinese hamster V79 cells. Can Res, 47: 206–209.


  1. Çelik A, Eke D, 2011, The assessment of cytotoxicity and genotoxicity of tetracycline antibiotic in human blood lymphocytes using CBMN and SCE analysis, in vitro. Int J Hum Gen, 11: 23–29.


  1. Hagmar L, Bonassi S, Strömberg U, et al., 1998, Chromosomal aberrations in lymphocytes predict human cancer: A report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Can Res, 58: 4117–4121.
Conflict of interest
All the authors declare that they have no competing interests.
Back to top
INNOSC Theranostics and Pharmacological Sciences, Electronic ISSN: 2705-0823 Published by AccScience Publishing